5-Methoxy-2-[6-[4-(2-methylsulfanylphenyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-1-yl]benzenesulfonamide | 885021-97-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Methoxy-2-[6-[4-(2-methylsulfanylphenyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-1-yl]benzenesulfonamide
• CAS: 885021-97-6
• 化学式: C₂₇H₂₃F₃N₄O₄S₂
• 分子量: 588.631
• InChiKey: MZJXCNKDKDBQBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  5-Methoxy-2-[6-[4-(2-methylsulfanylphenyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-1-yl]benzenesulfonamide 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-{6-[4-(2-methanesulfonylphenyl)phenyl]-7-oxo-3-(trifluoromethyl)-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-1-yl}-5-methoxybenzene-1-sulfonamide
  参考文献：
  名称：

  Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

  摘要：

  The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2'-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-1-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.027
• 作为产物：
  描述：

  1-(4-碘苯基)-3-吗啉基-5,6-二氢吡啶-2(1H)-酮 在 盐酸 、 4-二甲氨基吡啶 、 potassium phosphate 、 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 生成 5-Methoxy-2-[6-[4-(2-methylsulfanylphenyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-1-yl]benzenesulfonamide
  参考文献：
  名称：

  Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties

  摘要：

  The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2'-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-1-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.027

文献信息

• US7381732B2
  申请人：——

  公开号：US7381732B2

  公开（公告）日：2008-06-03
• Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
  作者：Donald J.P. Pinto、Robert A. Galemmo、Mimi L. Quan、Michael J. Orwat、Charles Clark、Renhua Li、Brian Wells、Francis Woerner、Richard S. Alexander、Karen A. Rossi、Angela Smallwood、Pancras C. Wong、Joseph M. Luettgen、Alan R. Rendina、Robert M. Knabb、Kan He、Ruth R. Wexler、Patrick Y.S. Lam

  DOI：10.1016/j.bmcl.2006.08.027

  日期：2006.11

  The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2'-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-1-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations. (c) 2006 Elsevier Ltd. All rights reserved.